Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma

Diagnostic Pathology

Volumn 5, Issue 1, 2010, Pages

  Štifter, Sanja ^a   Babarović, Emina ^a   Valković, Toni ^b   Seili Bekafigo, Irena ^b   Štemberger, Christophe ^b   Načinović, Antica ^b   Lučin, Ksenija ^a   Jonjić, Nives ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b KBC RIJEKA   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

SDC1 PROTEIN, HUMAN; SYNDECAN 1;

ADULT; AGED; ARTICLE; BIOPSY; BONE MARROW; BONE MARROW EXAMINATION; CANCER STAGING; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; NEEDLE BIOPSY; PATHOLOGY; PLASMA CELL; PREDICTIVE VALUE; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; BIOPSY, NEEDLE; BONE MARROW; BONE MARROW EXAMINATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PLASMA CELLS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SYNDECAN-1; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952252075     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-5-30     Document Type: Article

References (27)

1. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Methods for estimation of bone marrow plasma cell involvement in myeloma: predictive value for response and survival in patients undergoing autologous stem cell transplantation. Am J Hematol 2001, 68:269-275. 10.1002/ajh.10003, 11754416.
2. Provan D, Singer CRJ, Baglin T, et al. Oxford handbook of clinical haematology 2006, 266. Oxford: Oxford University Press, Second.
3. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of tumours of Haematopoietic and Lymphoid Tissues 2008, Lyon: IARC Press, 4.
4. Sukpanichnant S, Cousar JB, Leelasiri A, et al. Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation. Hum Pathol 1994, 25:308-318. 10.1016/0046-8177(94)90204-6, 8150462.
5. Charles KS, Winfield DA, Angel C, et al. Audit of bone marrow aspirates and trephine biopsies in multiple myeloma - a single centre study. Clin Lab Haematol 2004, 26:403-406. 10.1111/j.1365-2257.2004.00646.x, 15595998.
6. Wei A, Westerman D, Feleppa F, et al. Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma. Haematologica 2005, 90:1147-1149.
7. Brunning R, McKenna RW. Atlas of tumor pathology. Tumors of the bone marrow 1994, 323-367. Washington, DC: Armed Forces Institute of Pathology, American Registry of Pathology.
8. Bartl R, Frisch B, Fateh-Moghadam A, et al. Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases. Am J Clin Pathol 1987, 87:342-355.
9. Carter A, Hocherman I, Linn S, et al. Prognostic significance of plasma cell morphology in multiple myeloma. Cancer 1987, 60:1060-1065. 10.1002/1097-0142(19870901)60:5<1060::AID-CNCR2820600522>3.0.CO;2-3, 3607725.
10. Subramanian R, Basu D, Dutta TK. Prognostic significance of bone marrow histology in multiple myeloma. Indian J Cancer 2009, 46:40-45. 10.4103/0019-509X.48594, 19282565.
11. International Myeloma Working Group Criteria for the classification of monoclonal gammapathias, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757. 10.1046/j.1365-2141.2003.04355.x, 12780789, International Myeloma Working Group.
12. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998, 102:1115-1123. 10.1046/j.1365-2141.1998.00930.x, 9753033.
13. Handa U, Chhabra S, Mohan H. Plasma cell tumours: cytomorphological features in a series of 12 cases diagnosed on fine needle aspiration cytology. Cytopathology 2009,
14. Costes V, Magen V, Legoluffe E, et al. The Mi 15 monoclonal antibody (anti-syndecan-1) is reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol 1999, 30:1405-1411. 10.1016/S0046-8177(99)90160-0, 10667416.
15. Chilosi M, Adami F, Lestani M, et al. CD 138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies. Mod Pathol 1999, 12:1101-1106.
16. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, et al. Syndecan-1(CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. od Pathol 2001, 14:M1052-1058.
17. Ng AP, Wei A, Bhurani D, et al. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica 2006, 91:972-975.
18. Al-Quran SZ, Yang L, Magill JM, et al. Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry. Hum Pathol 2007, 38:1779-1787. 10.1016/j.humpath.2007.04.010, 17714757.
19. Joshi R, Horncastle D, Elderfield K, et al. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients. J Clin Pathol 2008, 61:213-216. 10.1136/jcp.2007.049130, 17526802.
20. Went P, Mayer S, Oberholzer M, et al. Plasma cell quantification in bone marrow by computer-assisted image analysis. Histol Histopathol 2006, 21:951-956.
21. Fabian P, Moulis M. Options for histological examination of bone marrow during diagnosis of multiple myeloma. Vnitr Lek 2006, 52(Suppl 2):66-70.
22. Singhal N, Singh T, Singh ZN, et al. Histomorphology of multiple myeloma on bone marrow biopsy. Indian J Pathol Microbiol 2004, 47:359-363.
23. Schambeck CM, Bartl R, Höchtlen-Vollmar W, et al. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin. Am J Clin Pathol 1996, 106:64-68.
24. Cetto GL, Iannucci A, Perini A, et al. Bone marrow evaluation: the relative merits of particle sections and smear preparations. Appl Pathol 1983, 1:181-193.
25. Scudla V, Adam Z. Diagnostic importance and pitfalls of evaluating bone marrow smear preparation in multiple myeloma. Vnitr Lek 2006, 52(Suppl 2):55-65.
26. Buss DH, Prichard RW, Hartz JW, et al. Comparison of the usefulness of bone marrow sections and smears in diagnosis of multiple myeloma. Hematol Pathol 1987, 1:35-43.
27. Terpstra WE, Lokhorst HM, Blomjous F, et al. Comparison of plasma cell infiltration in bone marrow biopsies and aspirates in patients with multiple myeloma. Br J Haematol 1992, 82:46-49. 10.1111/j.1365-2141.1992.tb04592.x, 1419801.